Showing 1161-1170 of 1310 results for "".
- Promius Receives FDA Approval for Sernivo Spray for Psoriasishttps://practicaldermatology.com/news/promius-receives-fda-approval-for-sernivo-spray-for-psoriasis/2458715/Dr. Reddy’s US subsidiary Promius Pharma received FDA approval for Sernivo (betamethasone dipropionate) Spray 0.05%. Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch
- Alastin SkinCare Appoints Lynn Salo to Board of Directorshttps://practicaldermatology.com/news/alastin-skincare-appoints-linda-salo-to-board-of-directors/2458719/Lynn Salo is now a member of ALASTIN™ Skincare, Inc.’s board of directors. Ms. Salo has 27 years of experience with Allergan in the U.S., Canada, and Europe, including her role as Vice President, Sales and Marketing for the Facial Aesthetic
- Survey: When it Come to Facial Aging Concerns, It's Like Mother, Like Daughterhttps://practicaldermatology.com/news/survey-when-it-come-to-facial-aging-concerns-its-like-mother-like-daughter/2458720/Galderma’s latest campaign Mom Genes™ aims to change the way moms and daughters talk about and approach facial aging. Fully 82 percent of moms hope facial aging is easier for their daughters, but more than half never talk about it togethe
- Meet the Neocutis' Family's Newest Add: Micro-Firm Neck and Décolleté Rejuvenating Complexhttps://practicaldermatology.com/news/meet-the-neocutis-familys-newest-add-micro-firm-neck-and-dcollet-rejuvenating-complex/2458723/Neocutis’ Micro-Firm Neck and Décolleté Rejuvenating Complex is slated to hit physician’s offices in March 2016. The cream, which will be the newest addition to the Neocutis family of anti-aging products, targets the delicate
- Bristol-Myers Squibb's Opdivo + Yervoy Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Statushttps://practicaldermatology.com/news/bristol-myers-squibbs-opdivo-yervoy-regimen-receives-expanded-fda-approval-in-unresectable-or-metastatic-melanoma-across-braf-status/2458732/The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is
- FDA Approves Updated Label for New Dosing Regimen for Allergan's Dalvancehttps://practicaldermatology.com/news/fda-approves-updated-label-for-new-dosing-regimen-for-allergans-dalvance/2458741/The FDA has approved Allergan plc’s supplemental new drug application (sNDA) to update the label for Dalvance® (dalbavancin) for injection. The expanded label will include a single dose administered as a 30-minute intravenous (IV) infusion of Dalvance for the treatment o
- ASDS Announces President's Award Recipientshttps://practicaldermatology.com/news/asds-announces-presidents-award-recipients/2458752/The American Society for Dermatologic Surgery honored four of its members with a President’s Award for contributing to the Society or the medical specialty in an extraordinary or unique way. George J. Hruza, MD, MBA, presented the awards in his final d
- Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisorhttps://practicaldermatology.com/news/psoria-shield-inc-names-dr-steven-feldman-as-scientific-advisor/2458754/Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisor Wellness Center USA, Inc.’s wholly owned subsidiary, Psoria-Shield, Inc. (PSI) named Steven Feldman, MD, PhD as Scientific Advisor. Dr. Feldman is a Professor of Dermatology, Professor of Pathology, and Professor of
- Dermira Completes Patient Enrollment for Third Cimzia Phase 3 Trial in Psoriasis Programhttps://practicaldermatology.com/news/dermira-completes-patient-enrollment-for-third-cimzia-phase-3-trial-in-psoriasis-program/2458760/Dermira, Inc., completed its patient enrollment for the CIMPACT clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. The CIMPACT study is the third and final clinical trial of the CIMZIA Phase 3 development program in moderate-to-s
- Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absencehttps://practicaldermatology.com/news/valeant-announces-j-michael-pearson-will-be-on-medical-leave-of-absence/2458770/Valeant Pharmaceuticals International, Inc. announced that chairman and chief executive officer J. Michael Pearson will be on a medical leave of absence, effective immediately. The company's board of directors has created an Office of the Chief Executive Officer, which will include Robert Cha